Screener
Dianthus Therapeutics DNTH Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Short-term investments | 483,592 | 353,208 |
| Accounts receivable, net | 1,230 | 52 |
| Prepaid expenses and other current assets | 7,422 | 5,091 |
| Total current assets | 1,119,911 | 409,438 |
| Long-term investments | 113,868 | 110,135 |
| Property and equipment, net | 274 | 296 |
| Right-of-use operating lease assets | 1,293 | 1,337 |
| Other assets and restricted cash | 11,538 | 9,716 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's total current assets?
- Dianthus Therapeutics (DNTH) reported total current assets of $1.12B in Q1 2026.
- How has Dianthus Therapeutics's total current assets changed year-over-year?
- Dianthus Therapeutics's total current assets increased by 313.3% year-over-year, from $271M to $1.12B.
- What is the long-term trend for Dianthus Therapeutics's total current assets?
- Over 5 years (2020 to 2025), Dianthus Therapeutics's total current assets has grown at a 22.0% compound annual growth rate (CAGR), from $151.53M to $409.44M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Dianthus Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude